Tyra Biosciences, Inc. (TYRA)
Nasdaq: TYRA · Pharmaceutical Preparations · Carlsbad, CA · filing with the SEC since 2021
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Report filed | Mar 2, 2026 | Mar 27, 2025 | Mar 19, 2024 | Mar 22, 2023 | Mar 3, 2022 | · |
| Research and development | 102,928 | 80,077 | 62,518 | 43,008 | 20,636 | 7,203 |
| General and administrative | 29,834 | 24,100 | 17,427 | 15,919 | 5,652 | 2,094 |
| Total operating expenses | 132,762 | 104,177 | 79,945 | 58,927 | 26,288 | 9,297 |
| Operating income | -132,762 | -104,177 | -79,945 | -58,927 | -26,288 | -9,297 |
| Total non-operating income (expense) | 12,815 | 17,696 | 10,811 | 3,602 | -6 | -39 |
| Income tax expense | 0 | 0 | 0 | 2 | 1 | 1 |
| Net income | -119,947 | -86,481 | -69,134 | -55,325 | -26,294 | -9,336 |
| Earnings per share, basic | -2.01 | -1.51 | -1.62 | -1.32 | -1.91 | · |
| Earnings per share, diluted | -2.01 | -1.51 | -1.62 | -1.32 | -1.91 | · |
| Earnings per share, basic and diluted | · | · | · | · | -1.91 | -6.05 |
| Weighted average shares, basic | 59,602,328 | 57,217,746 | 42,704,876 | 41,883,904 | 13,780,546 | · |
| Weighted average shares, diluted | 59,602,328 | 57,217,746 | 42,704,876 | 41,883,904 | 13,780,546 | · |
| Weighted average shares, basic and diluted | · | · | · | · | 13,780,546 | 1,542,174 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted